Literature DB >> 3367936

Prevalence of hemochromatosis among 11,065 presumably healthy blood donors.

C Q Edwards1, L M Griffen, D Goldgar, C Drummond, M H Skolnick, J P Kushner.   

Abstract

There is evidence that iron loading and organ damage can be prevented in patients with hemochromatosis if prophylactic phlebotomy is employed early in the disease--findings emphasizing the importance of early detection before clinical signs occur. This study was designed to determine the efficacy of transferrin saturation as a screening tool for hemochromatosis and to assess the frequency of homozygosity for the HLA-linked hemochromatosis gene in a healthy population. We screened 11,065 presumably healthy blood donors (5840 men and 5225 women). Donors with transferrin saturations of 62 percent or more after an overnight fast were considered potential homozygotes and were asked to undergo liver biopsy and pedigree analysis. The frequency of values for transferrin saturation of 62 or higher in men was 0.008 and in women 0.003. Thirty-eight persons with values higher than 62 were studied in detail; 35 underwent liver biopsy. Liver iron stores ranged from normal to markedly increased. Twelve siblings with an identical HLA match to a proband underwent liver biopsy, and 11 had increased liver iron stores. According to likelihood analysis of the pedigrees, 26 of the 38 probands were homozygotes, and 12 were heterozygotes. The estimated frequency of homozygosity was based on the data in men, because the threshold value of 62 for the transferrin saturation identified only half as many female homozygotes as expected. The frequency of homozygosity was 0.0045, corresponding to a gene frequency of 0.067. The value of population screening is demonstrated in these studies by the detection of homozygotes before clinical manifestations of hemochromatosis occur.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367936     DOI: 10.1056/NEJM198805263182103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  99 in total

1.  Population screening for haemochromatosis.

Authors:  P C Adams
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

2.  The frequency of C282Y and H63D mutations in Hemochromatosis gene in native Estonians.

Authors:  P Pärlist; A V Mikelsaar; G Tasa; L Beckman
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

3.  Molecular biology and the diagnosis and treatment of liver diseases.

Authors:  Howard J Worman; Lin Feng; Naoto Mamiya
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

Review 4.  Should all patients with diabetes mellitus be screened for hemochromatosis?

Authors:  Paula Cifuentes Henderson; Patrick Dowling; Rikio Ozaki
Journal:  West J Med       Date:  2002-03

5.  Global prevalence of putative haemochromatosis mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; J D Shearman; K J Robson
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

Review 6.  Molecular pathogenesis of iron overload.

Authors:  D Trinder; C Fox; G Vautier; J K Olynyk
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

7.  Sequence variation and haplotype structure at the human HFE locus.

Authors:  Christopher Toomajian; Martin Kreitman
Journal:  Genetics       Date:  2002-08       Impact factor: 4.562

8.  Reference distributions for serum iron and transferrin saturation: a comparison of a large cohort to the world's literature.

Authors:  Robert F Ritchie; Glenn E Palomaki; Louis M Neveux; Olga Navolotskaia; Thomas B Ledue; Wendy Y Craig
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

9.  Fatty liver in H63D homozygotes with hyperferritinemia.

Authors:  Giada Sebastiani; Daniel F Wallace; Susan E Davies; Vasu Kulhalli; Ann P Walker; James S Dooley
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

10.  Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum.

Authors:  A Waheed; S Parkkila; J Saarnio; R E Fleming; X Y Zhou; S Tomatsu; R S Britton; B R Bacon; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.